1921
Control and Elimination of Plasmodium vivax Malaria: The Evidence Base
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract

is the most widespread human malaria, putting 2.5 billion people at risk of infection. Its unique biological and epidemiological characteristics pose challenges to control strategies that have been principally targeted against . Unlike , infections have typically low blood-stage parasitemia with gametocytes emerging before illness manifests, and dormant liver stages causing relapses. These traits affect both its geographic distribution and transmission patterns. Asymptomatic infections, high-risk groups, and resulting case burdens are described in this review. Despite relatively low prevalence measurements and parasitemia levels, along with high proportions of asymptomatic cases, this parasite is not benign. can be associated with severe and even fatal illness. Spreading resistance to chloroquine against the acute attack, and the operational inadequacy of primaquine against the multiple attacks of relapse, exacerbates the risk of poor outcomes among the tens of millions suffering from infection each year. Without strategies accounting for these -specific characteristics, progress toward elimination of endemic malaria transmission will be substantially impeded.

[open-access] This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.16-0141
2016-12-28
2017-09-19
Loading full text...

Full text loading...

/deliver/fulltext/14761645/95/6_Suppl/15.html?itemId=/content/journals/10.4269/ajtmh.16-0141&mimeType=html&fmt=ahah

References

  1. PATH, 2011. Staying the Course? Malaria Research and Development in a Time of Economic Uncertainty. Seattle, WA: PATH.
  2. Gething PW, Elyazar IR, Moyes CL, Smith DL, Battle KE, Guerra CA, Patil AP, Tatem AJ, Howes RE, Myers MF, George DB, Horby P, Wertheim HF, Price RN, Mueller I, Baird JK, Hay SI, , 2012. A long neglected world malaria map: Plasmodium vivax endemicity in 2010. PLoS Negl Trop Dis 6: e1814.[Crossref]
  3. Gething PW, Patil AP, Smith DL, Guerra CA, Elyazar IR, Johnston GL, Tatem AJ, Hay SI, , 2011. A new world malaria map: Plasmodium falciparum endemicity in 2010. Malar J 10: 378.[Crossref]
  4. Mueller I, Galinski MR, Tsuboi T, Arevalo-Herrera M, Collins WE, King CL, , 2013. Natural acquisition of immunity to Plasmodium vivax: epidemiological observations and potential targets. Adv Parasitol 81: 77131.[Crossref]
  5. Baird JK, , 2013. Evidence and implications of mortality associated with acute Plasmodium vivax malaria. Clin Microbiol Rev 26: 3657.[Crossref]
  6. Baird JK, , 2009. Severe and fatal vivax malaria challenges ‘benign tertian malaria’ dogma. Ann Trop Paediatr 29: 251252.[Crossref]
  7. Price RN, Tjitra E, Guerra CA, Yeung S, White NJ, Anstey NM, , 2007. Vivax malaria: neglected and not benign. Am J Trop Med Hyg 77: 7987.
  8. Anstey NM, Douglas NM, Poespoprodjo JR, Price RN, , 2012. Plasmodium vivax: clinical spectrum, risk factors and pathogenesis. Adv Parasitol 80: 151201.[Crossref]
  9. Barcus MJ, Basri H, Picarima H, Manyakori C, Sekartuti Elyazar I, Bangs MJ, Maguire JD, Baird JK, , 2007. Demographic risk factors for severe and fatal vivax and falciparum malaria among hospital admissions in northeastern Indonesian Papua. Am J Trop Med Hyg 77: 984991.
  10. Bassat Q, Alonso PL, , 2011. Defying malaria: fathoming severe Plasmodium vivax disease. Nat Med 17: 4849.[Crossref]
  11. Douglas NM, Anstey NM, Buffet PA, Poespoprodjo JR, Yeo TW, White NJ, Price RN, , 2012. The anaemia of Plasmodium vivax malaria. Malar J 11: 135.[Crossref]
  12. Genton B, D'Acremont V, Rare L, Baea K, Reeder JC, Alpers MP, Muller I, , 2008. Plasmodium vivax and mixed infections are associated with severe malaria in children: a prospective cohort study from Papua New Guinea. PLoS Med 5: e127.[Crossref]
  13. Kochar DK, Tanwar GS, Khatri PC, Kochar SK, Sengar GS, Gupta A, Kochar A, Middha S, Acharya J, Saxena V, Pakalapati D, Garg S, Das A, , 2010. Clinical features of children hospitalized with malaria—a study from Bikaner, northwest India. Am J Trop Med Hyg 83: 981989.[Crossref]
  14. Lacerda MV, Fragoso SC, Alecrim MG, Alexandre MA, Magalhaes BM, Siqueira AM, Ferreira LC, Araujo JR, Mourao MP, Ferrer M, Castillo P, Martin-Jaular L, Fernandez-Becerra C, del Portillo H, Ordi J, Alonso PL, Bassat Q, , 2012. Postmortem characterization of patients with clinical diagnosis of Plasmodium vivax malaria: to what extent does this parasite kill? Clin Infect Dis 55: e67e74.[Crossref]
  15. Lacerda MV, Mourao MP, Alexandre MA, Siqueira AM, Magalhaes BM, Martinez-Espinosa FE, Filho FS, Brasil P, Ventura AM, Tada MS, Couto VS, Silva AR, Silva RS, Alecrim MG, , 2012. Understanding the clinical spectrum of complicated Plasmodium vivax malaria: a systematic review on the contributions of the Brazilian literature. Malar J 11: 12.[Crossref]
  16. Lança EFC, Magalhães BML, Vitor-Silva S, Siqueira AM, Benzecry SG, Alexandre MAA, O'Brien C, Bassat Q, Lacerda MVG, , 2012. Risk factors and characterization of Plasmodium vivax-associated admissions to pediatric intensive care units in the Brazilian Amazon. PLoS One 7: e35406.[Crossref]
  17. Mahgoub H, Gasim GI, Musa IR, Adam I, , 2012. Severe Plasmodium vivax malaria among Sudanese children at New Halfa Hospital, eastern Sudan. Parasit Vectors 5: 154.[Crossref]
  18. Price RN, Douglas NM, Anstey NM, , 2009. New developments in Plasmodium vivax malaria: severe disease and the rise of chloroquine resistance. Curr Opin Infect Dis 22: 430435.[Crossref]
  19. Quispe AM, Pozo E, Guerrero E, Durand S, Baldeviano GC, Edgel KA, Graf PCF, Lescano AG, , 2014. Plasmodium vivax hospitalizations in a monoendemic malaria region: severe vivax malaria? Am J Trop Med Hyg 91: 1117.[Crossref]
  20. Tjitra E, Anstey NM, Sugiarto P, Warikar N, Kenangalem E, Karyana M, Lampah DA, Price RN, , 2008. Multidrug-resistant Plasmodium vivax associated with severe and fatal malaria: a prospective study in Papua, Indonesia. PLoS Med 5: e128.[Crossref]
  21. Baird JK, , 2010. Eliminating malaria—all of them. Lancet 376: 18831885.[Crossref]
  22. Bockarie MJ, Dagoro H, , 2006. Are insecticide-treated bednets more protective against Plasmodium falciparum than Plasmodium vivax-infected mosquitoes? Malar J 5: 15.[Crossref]
  23. Bousema T, Drakeley C, , 2011. Epidemiology and infectivity of Plasmodium falciparum and Plasmodium vivax gametocytes in relation to malaria control and elimination. Clin Microbiol Rev 24: 377410.[Crossref]
  24. Luxemburger C, Perea WA, Delmas G, Pruja C, Pecoul B, Moren A, , 1994. Permethrin-impregnated bed nets for the prevention of malaria in schoolchildren on the Thai-Burmese border. Trans R Soc Trop Med Hyg 88: 155159.[Crossref]
  25. Shanks GD, , 2012. Control and elimination of Plasmodium vivax . Adv Parasitol 80: 301341.[Crossref]
  26. Tanner M, Greenwood B, Whitty CJ, Ansah EK, Price RN, Dondorp AM, von Seidlein L, Baird JK, Beeson JG, Fowkes FJ, Hemingway J, Marsh K, Osier F, , 2015. Malaria eradication and elimination: views on how to translate a vision into reality. BMC Med 13: 167.[Crossref]
  27. Livingstone FB, , 1984. The Duffy blood groups, vivax malaria, and malaria selection in human populations: a review. Hum Biol 56: 413425.
  28. Howes RE, Patil AP, Piel FB, Nyangiri OA, Kabaria CW, Gething PW, Zimmerman PA, Barnadas C, Beall CM, Gebremedhin A, Menard D, Williams TN, Weatherall DJ, Hay SI, , 2011. The global distribution of the Duffy blood group. Nat Commun 2: 266.[Crossref]
  29. Ménard D, Barnadas C, Bouchier C, Henry-Halldin C, Gray LR, Ratsimbasoa A, Thonier V, Carod JF, Domarle O, Colin Y, Bertrand O, Picot J, King CL, Grimberg BT, Mercereau-Puijalon O, Zimmerman PA, , 2010. Plasmodium vivax clinical malaria is commonly observed in Duffy-negative Malagasy people. Proc Natl Acad Sci USA 107: 59675971.[Crossref]
  30. Zimmerman PA, Ferreira MU, Howes RE, Mercereau-Puijalon O, , 2013. Red blood cell polymorphism and susceptibility to Plasmodium vivax . Adv Parasitol 81: 2776.[Crossref]
  31. Guerra CA, Howes RE, Patil AP, Gething PW, Van Boeckel TP, Temperely WH, Kabaria CW, Tatem AJ, Manh BH, Elyazar I, Baird JK, Snow RW, Hay SI, , 2010. The international limits and population at risk of Plasmodium vivax transmission in 2009. PLoS Negl Trop Dis 4: e774.[Crossref]
  32. Howes RE, Reiner RC, Jr Battle KE, Longbottom J, Mappin B, Ordanovich D, Tatem AJ, Drakeley C, Gething PW, Zimmerman PA, Smith DL, Hay SI, , 2015. Plasmodium vivax transmission in Africa. PLoS Negl Trop Dis 9: e0004222.[Crossref]
  33. Battle KE, Gething PW, Elyazar IR, Moyes CL, Sinka ME, Howes RE, Guerra CA, Price RN, Baird KJ, Hay SI, , 2012. The global public health significance of Plasmodium vivax . Adv Parasitol 80: 1111.[Crossref]
  34. Balk DL, Deichmann U, Yetman G, Pozzi F, Hay SI, Nelson A, , 2006. Determining global population distribution: methods, applications and data. Adv Parasitol 62: 119156.[Crossref]
  35. CIESIN/IFPRI/WB/CIAT, 2007. Global Rural Urban Mapping Project (GRUMP) alpha: Gridded Population of the World, Version 2, with Urban Reallocation (GPW-UR). Available at: http://sedac.ciesin.columbia.edu/gpw. Accessed November 25, 2011.
  36. World Health Organization, 2015. World Malaria Report 2015. Geneva, Switzerland: World Health Organization, 280.
  37. Mueller I, Zimmerman PA, Reeder JC, , 2007. Plasmodium malariae and Plasmodium ovale–the “bashful” malaria parasites. Trends Parasitol 23: 278283.[Crossref]
  38. Moreira CM, Abo-Shehada M, Price RN, Drakeley CJ, , 2015. A systematic review of sub-microscopic Plasmodium vivax infection. Malar J 14: 360.[Crossref]
  39. Mueller I, Galinski MR, Baird JK, Carlton JM, Kochar DK, Alonso PL, del Portillo HA, , 2009. Key gaps in the knowledge of Plasmodium vivax, a neglected human malaria parasite. Lancet Infect Dis 9: 555566.[Crossref]
  40. da Silva NS, da Silva-Nunes M, Malafronte RS, Menezes MJ, D'Arcadia RR, Komatsu NT, Scopel KK, Braga EM, Cavasini CE, Cordeiro JA, Ferreira MU, , 2010. Epidemiology and control of frontier malaria in Brazil: lessons from community-based studies in rural Amazonia. Trans R Soc Trop Med Hyg 104: 343350.[Crossref]
  41. Harris I, Sharrock WW, Bain LM, Gray KA, Bobogare A, Boaz L, Lilley K, Krause D, Vallely A, Johnson ML, Gatton ML, Shanks GD, Cheng Q, , 2010. A large proportion of asymptomatic Plasmodium infections with low and sub-microscopic parasite densities in the low transmission setting of Temotu Province, Solomon Islands: challenges for malaria diagnostics in an elimination setting. Malar J 9: 254.[Crossref]
  42. Katsuragawa TH, Gil LH, Tada MS, de Almeida e Silva A, Costa JD, Araujo M da S, Escobar AL, da Silva LH, , 2010. The dynamics of transmission and spatial distribution of malaria in riverside areas of Porto Velho, Rondonia, in the Amazon region of Brazil. PLoS One 5: e9245.[Crossref]
  43. Mueller I, Widmer S, Michel D, Maraga S, McNamara DT, Kiniboro B, Sie A, Smith TA, Zimmerman PA, , 2009. High sensitivity detection of Plasmodium species reveals positive correlations between infections of different species, shifts in age distribution and reduced local variation in Papua New Guinea. Malar J 8: 41.[Crossref]
  44. Steenkeste N, Rogers WO, Okell L, Jeanne I, Incardona S, Duval L, Chy S, Hewitt S, Chou M, Socheat D, Babin FX, Ariey F, Rogier C, , 2010. Sub-microscopic malaria cases and mixed malaria infection in a remote area of high malaria endemicity in Rattanakiri Province, Cambodia: implication for malaria elimination. Malar J 9: 108.[Crossref]
  45. Imwong M, Nguyen TN, Tripura R, Peto TJ, Lee SJ, Lwin KM, Suangkanarat P, Jeeyapant A, Vihokhern B, Wongsaen K, Van Hue D, Dong le T, Nguyen TU, Lubell Y, von Seidlein L, Dhorda M, Promnarate C, Snounou G, Malleret B, Renia L, Keereecharoen L, Singhasivanon P, Sirithiranont P, Chalk J, Nguon C, Hien TT, Day N, White NJ, Dondorp A, Nosten F, , 2015. The epidemiology of subclinical malaria infections in southeast Asia: findings from cross-sectional surveys in Thailand-Myanmar border areas, Cambodia, and Vietnam. Malar J 14: 381.[Crossref]
  46. Cheng Q, Cunningham J, Gatton ML, , 2015. Systematic review of sub-microscopic P. vivax infections: prevalence and determining factors. PLoS Negl Trop Dis 9: e3413.[Crossref]
  47. Waltmann A, Darcy AW, Harris I, Koepfli C, Lodo J, Vahi V, Piziki D, Shanks GD, Barry AE, Whittaker M, Kazura JW, Mueller I, , 2015. High rates of asymptomatic, sub-microscopic Plasmodium vivax infection and disappearing Plasmodium falciparum malaria in an area of low transmission in Solomon Islands. PLoS Negl Trop Dis 9: e0003758.[Crossref]
  48. Mayxay M, Pukrittayakamee S, Newton PN, White NJ, , 2004. Mixed-species malaria infections in humans. Trends Parasitol 20: 233240.[Crossref]
  49. Douglas NM, Nosten F, Ashley EA, Phaiphun L, van Vugt M, Singhasivanon P, White NJ, Price RN, , 2011. Plasmodium vivax recurrence following falciparum and mixed species malaria: risk factors and effect of antimalarial kinetics. Clin Infect Dis 52: 612620.[Crossref]
  50. Machado Siqueira A, Lopes Magalhaes BM, Cardoso Melo G, Ferrer M, Castillo P, Martin-Jaular L, Fernandez-Becerra C, Ordi J, Martinez A, Lacerda MV, del Portillo HA, , 2012. Spleen rupture in a case of untreated Plasmodium vivax infection. PLoS Negl Trop Dis 6: e1934.[Crossref]
  51. Battle KE, Karhunen MS, Bhatt S, Gething PW, Howes RE, Golding N, Van Boeckel T, Messina JP, Shanks GD, Smith DL, Baird JK, Hay SI, , 2014. Geographical variation in Plasmodium vivax relapse. Malar J 13: 144.[Crossref]
  52. White NJ, Imwong M, , 2012. Relapse. Adv Parasitol 80: 113150.[Crossref]
  53. Baird JK, , 2004. Chloroquine resistance in Plasmodium vivax . Antimicrob Agents Chemother 48: 40754083.[Crossref]
  54. Imwong M, Snounou G, Pukrittayakamee S, Tanomsing N, Kim JR, Nandy A, Guthmann JP, Nosten F, Carlton J, Looareesuwan S, Nair S, Sudimack D, Day NP, Anderson TJ, White NJ, , 2007. Relapses of Plasmodium vivax infection usually result from activation of heterologous hypnozoites. J Infect Dis 195: 927933.[Crossref]
  55. Koepfli C, Ross A, Kiniboro B, Smith TA, Zimmerman PA, Siba P, Mueller I, Felger I, , 2011. Multiplicity and diversity of Plasmodium vivax infections in a highly endemic region in Papua New Guinea. PLoS Negl Trop Dis 5: e1424.[Crossref]
  56. Betuela I, Rosanas-Urgell A, Kiniboro B, Stanisic DI, Samol L, de Lazzari E, del Portillo HA, Siba P, Alonso PL, Bassat Q, Mueller I, , 2012. Relapses contribute significantly to the risk of Plasmodium vivax infection and disease in Papua New Guinean children 1–5 years of age. J Infect Dis 206: 17711780.[Crossref]
  57. Nelwan EJ, Ekawati LL, Tjahjono B, Setiabudy R, Sutanto I, Chand K, Ekasari T, Djoko D, Basri H, Taylor WR, Duparc S, Subekti D, Elyazar I, Noviyanti R, Sudoyo H, Baird JK, , 2015. Randomized trial of primaquine hypnozoitocidal efficacy when administered with artemisinin-combined blood schizontocides for radical cure of Plasmodium vivax in Indonesia. BMC Med 13: 294.[Crossref]
  58. Sutanto I, Tjahjono B, Basri H, Taylor WR, Putri FA, Meilia RA, Setiabudy R, Nurleila S, Ekawati LL, Elyazar I, Farrar J, Sudoyo H, Baird JK, , 2013. Randomized, open-label trial of primaquine against vivax malaria relapse in Indonesia. Antimicrob Agents Chemother 57: 11281135.[Crossref]
  59. Coatney GR, Cooper WC, , 1948. Recrudescence and relapse in vivax malaria. Proceedings of the 4th International Congress on Tropical Medicine, Vol. 1. Washington, DC: US Government Printing Office, 629639.
  60. Garnham PC, Bray RS, Bruce-Chwatt LJ, Draper CC, Killick-Kendrick R, Sergiev PG, Tiburskaja NA, Shute PG, Maryon M, , 1975. A strain of Plasmodium vivax characterized by prolonged incubation: morphological and biological characteristics. Bull World Health Organ 52: 2132.
  61. Winckel CWF, , 1955. Long latency in Plasmodium vivax infections in a temperate zone. Doc Med Geogr Trop 7: 292298.
  62. Coatney GR, Collins WE, Contacos PG, , 1971. Plasmodium vivax. The Primate Malarias. Bethesda, MD: U.S. National Institute of Allergy and Infectious Diseases, 4367.
  63. Baird JK, Rieckmann KH, , 2003. Can primaquine therapy for vivax malaria be improved? Trends Parasitol 19: 115120.[Crossref]
  64. Shute PG, Lupascu G, Branzei P, Maryon M, Constantinescu P, Bruce-Chwatt LJ, Draper CC, Killick-Kendrick R, Garnham PC, , 1976. A strain of Plasmodium vivax characterized by prolonged incubation: the effect of numbers of sporozoites on the length of the prepatent period. Trans R Soc Trop Med Hyg 70: 474481.[Crossref]
  65. White NJ, , 2011. Determinants of relapse periodicity in Plasmodium vivax malaria. Malar J 10: 297.[Crossref]
  66. Shanks GD, White NJ, , 2013. The activation of vivax malaria hypnozoites by infectious diseases. Lancet Infect Dis 13: 900906.[Crossref]
  67. Richie TL, , 1988. Interactions between malaria parasites infecting the same vertebrate host. Parasitology 96: 607639.[Crossref]
  68. Hulden L, Hulden L, , 2011. Activation of the hypnozoite: a part of Plasmodium vivax life cycle and survival. Malar J 10: 90.[Crossref]
  69. Macdonald G, , 1957. Local Features of Malaria. The Epidemiology and Control of Malaria. London, United Kingdom: Oxford University Press, 6399.
  70. Howes RE, Battle KE, Satyagraha AW, Baird JK, Hay SI, , 2013. G6PD deficiency: global distribution, genetic variants and primaquine therapy. Adv Parasitol 81: 133201.[Crossref]
  71. Cotter C, Sturrock HJ, Hsiang MS, Liu J, Phillips AA, Hwang J, Gueye CS, Fullman N, Gosling RD, Feachem RG, , 2013. The changing epidemiology of malaria elimination: new strategies for new challenges. Lancet 382: 900911.[Crossref]
  72. Smith DL, Guerra CA, Snow RW, Hay SI, , 2007. Standardizing estimates of the Plasmodium falciparum parasite rate. Malar J 6: 131.[Crossref]
  73. Smith T, Hii JL, Genton B, Muller I, Booth M, Gibson N, Narara A, Alpers MP, , 2001. Associations of peak shifts in age–prevalence for human malarias with bednet coverage. Trans R Soc Trop Med Hyg 95: 16.[Crossref]
  74. Senn N, Rarau P, Stanisic DI, Robinson L, Barnadas C, Manong D, Salib M, Iga J, Tarongka N, Ley S, Rosanas-Urgell A, Aponte JJ, Zimmerman PA, Beeson JG, Schofield L, Siba P, Rogerson SJ, Reeder JC, Mueller I, , 2012. Intermittent preventive treatment for malaria in Papua New Guinean infants exposed to Plasmodium falciparum and P. vivax: a randomized controlled trial. PLoS Med 9: e1001195.[Crossref]
  75. Michon P, Cole-Tobian JL, Dabod E, Schoepflin S, Igu J, Susapu M, Tarongka N, Zimmerman PA, Reeder JC, Beeson JG, Schofield L, King CL, Mueller I, , 2007. The risk of malarial infections and disease in Papua New Guinean children. Am J Trop Med Hyg 76: 9971008.
  76. Poespoprodjo JR, Fobia W, Kenangalem E, Lampah DA, Hasanuddin A, Warikar N, Sugiarto P, Tjitra E, Anstey NM, Price RN, , 2009. Vivax malaria: a major cause of morbidity in early infancy. Clin Infect Dis 48: 17041712.[Crossref]
  77. Koepfli C, Colborn KL, Kiniboro B, Lin E, Speed TP, Siba PM, Felger I, Mueller I, , 2013. A high force of Plasmodium vivax blood-stage infection drives the rapid acquisition of immunity in Papua New Guinean children. PLoS Negl Trop Dis 7: e2403.[Crossref]
  78. Fowkes FJ, Boeuf P, Beeson JG, , 2016. Immunity to malaria in an era of declining malaria transmission. Parasitology 143: 139153.[Crossref]
  79. Mendis K, Sina BJ, Marchesini P, Carter R, , 2001. The neglected burden of Plasmodium vivax malaria. Am J Trop Med Hyg 64: 97106.
  80. Phimpraphi W, Paul RE, Yimsamran S, Puangsa-art S, Thanyavanich N, Maneeboonyang W, Prommongkol S, Sornklom S, Chaimungkun W, Chavez IF, Blanc H, Looareesuwan S, Sakuntabhai A, Singhasivanon P, , 2008. Longitudinal study of Plasmodium falciparum and Plasmodium vivax in a Karen population in Thailand. Malar J 7: 99.[Crossref]
  81. Li N, Parker DM, Yang Z, Fan Q, Zhou G, Ai G, Duan J, Lee MC, Yan G, Matthews SA, Cui L, Wang Y, , 2013. Risk factors associated with slide positivity among febrile patients in a conflict zone of north-eastern Myanmar along the China-Myanmar border. Malar J 12: 361.[Crossref]
  82. Ciuca M, Ballif L, Chelarescu-Viera M, , 1934. Immunity in malaria. Trans R Soc Trop Med Hyg 24: 4.
  83. Qi Q, Guerra CA, Moyes CL, Elyazar IR, Gething PW, Hay SI, Tatem AJ, , 2012. The effects of urbanization on global Plasmodium vivax malaria transmission. Malar J 11: 403.[Crossref]
  84. Sinka ME, Bangs MJ, Manguin S, Chareonviriyaphap T, Patil AP, Temperley WH, Gething PW, Elyazar IR, Kabaria CW, Harbach RE, Hay SI, , 2011. The dominant Anopheles vectors of human malaria in the Asia-Pacific region: occurrence data, distribution maps and bionomic precis. Parasit Vectors 4: 89.[Crossref]
  85. Anvikar AR, Shah N, Dhariwal AC, Sonal GS, Pradhan MM, Ghosh SK, Valecha N, , 2016. Epidemiology of Plasmodium vivax malaria in India. Am J Trop Med Hyg 95 (Suppl 6): 108120.[Crossref]
  86. Sinka ME, Bangs MJ, Manguin S, Coetzee M, Mbogo CM, Hemingway J, Patil AP, Temperley WH, Gething PW, Kabaria CW, Okara RM, Van Boeckel T, Godfray HC, Harbach RE, Hay SI, , 2010. The dominant Anopheles vectors of human malaria in Africa, Europe and the Middle East: occurrence data, distribution maps and bionomic precis. Parasit Vectors 3: 117.[Crossref]
  87. Sinka ME, Rubio-Palis Y, Manguin S, Patil AP, Temperley WH, Gething PW, Van Boeckel T, Kabaria CW, Harbach RE, Hay SI, , 2010. The dominant Anopheles vectors of human malaria in the Americas: occurrence data, distribution maps and bionomic precis. Parasit Vectors 3: 72.[Crossref]
  88. Killeen GF, , 2014. Characterizing, controlling and eliminating residual malaria transmission. Malaria J 13: 330. doi:101186/1475-2875-13-330.[Crossref]
  89. Nyunt MH, Aye KM, Kyaw MP, Kyaw TT, Hlaing T, Oo K, Zaw NN, Aye TT, San NA, , 2014. Challenges in universal coverage and utilization of insecticide-treated bed nets in migrant plantation workers in Myanmar. Malar J 13: 211.[Crossref]
  90. World Health Organization and Malaria Consortium, 2011. Workshop to Consolidate Lessons Learned on BCC and Mobile/Migrant Populations in the Strategy to Contain Artemisinin Resistant Malaria. Meeting report, July 5–7, 2011. Luang Prabang, Lao PDR: World Health Organization and Malaria Consortium.
  91. Desai M, ter Kuile FO, Nosten F, McGready R, Asamoa K, Brabin B, Newman RD, , 2007. Epidemiology and burden of malaria in pregnancy. Lancet Infect Dis 7: 93104.[Crossref]
  92. WHO Evidence Review Group, 2012. Intermittent Preventative Treatment of Malaria in Pregnancy (IPTp) with Sulfadoxine-Pyrimethamine (SP). Meeting report, July 9–11, 2012. Geneva, Switzerland: World Health Organization.
  93. Rijken MJ, McGready R, Boel ME, Poespoprodjo R, Singh N, Syafruddin D, Rogerson S, Nosten F, , 2012. Malaria in pregnancy in the Asia-Pacific region. Lancet Infect Dis 12: 7588.[Crossref]
  94. Rodriguez-Morales AJ, Sanchez E, Vargas M, Piccolo C, Colina R, Arria M, Franco-Paredes C, , 2006. Pregnancy outcomes associated with Plasmodium vivax malaria in northeastern Venezuela. Am J Trop Med Hyg 74: 755757.
  95. Rogerson SJ, Hviid L, Duffy PE, Leke RF, Taylor DW, , 2007. Malaria in pregnancy: pathogenesis and immunity. Lancet Infect Dis 7: 105117.[Crossref]
  96. Poespoprodjo JR, Fobia W, Kenangalem E, Lampah DA, Warikar N, Seal A, McGready R, Sugiarto P, Tjitra E, Anstey NM, Price RN, , 2008. Adverse pregnancy outcomes in an area where multidrug-resistant Plasmodium vivax and Plasmodium falciparum infections are endemic. Clin Infect Dis 46: 13741381.[Crossref]
  97. Brabin BJ, Ginny M, Sapau J, Galme K, Paino J, , 1990. Consequences of maternal anaemia on outcome of pregnancy in a malaria endemic area in Papua New Guinea. Ann Trop Med Parasitol 84: 1124.[Crossref]
  98. Luxemburger C, Ricci F, Nosten F, Raimond D, Bathet S, White NJ, , 1997. The epidemiology of severe malaria in an area of low transmission in Thailand. Trans R Soc Trop Med Hyg 91: 256262.[Crossref]
  99. McGready R, Lee SJ, Wiladphaingern J, Ashley EA, Rijken MJ, Boel M, Simpson JA, Paw MK, Pimanpanarak M, Mu O, Singhasivanon P, White NJ, Nosten FH, , 2012. Adverse effects of falciparum and vivax malaria and the safety of antimalarial treatment in early pregnancy: a population-based study. Lancet Infect Dis 12: 388396.[Crossref]
  100. Baird JK, Hoffman SL, , 2004. Primaquine therapy for malaria. Clin Infect Dis 39: 13361345.[Crossref]
  101. Piel FB, Howes RE, Nyangiri OA, Moyes CL, Williams TN, Weatherall DJ, Hay SI, , 2013. Online biomedical resources for malaria-related red cell disorders. Hum Mutat 34: 937944.[Crossref]
  102. Kwiatkowski DP, , 2005. How malaria has affected the human genome and what human genetics can teach us about malaria. Am J Hum Genet 77: 171192.[Crossref]
  103. Piel FB, Patil AP, Howes RE, Nyangiri OA, Gething PW, Williams TN, Weatherall DJ, Hay SI, , 2010. Global distribution of the sickle cell gene and geographical confirmation of the malaria hypothesis. Nat Commun 1: 104.[Crossref]
  104. Cattani JA, Gibson FD, Alpers MP, Crane GG, , 1987. Hereditary ovalocytosis and reduced susceptibility to malaria in Papua New Guinea. Trans R Soc Trop Med Hyg 81: 705709.[Crossref]
  105. Rosanas-Urgell A, Lin E, Manning L, Rarau P, Laman M, Senn N, Grimberg BT, Tavul L, Stanisic DI, Robinson LJ, Aponte JJ, Dabod E, Reeder JC, Siba P, Zimmerman PA, Davis TM, King CL, Michon P, Mueller I, , 2012. Reduced risk of Plasmodium vivax malaria in Papua New Guinean children with southeast Asian ovalocytosis in two cohorts and a case-control study. PLoS Med 9: e1001305.[Crossref]
  106. Leslie T, Briceno M, Mayan I, Mohammed N, Klinkenberg E, Sibley CH, Whitty CJ, Rowland M, , 2010. The impact of phenotypic and genotypic G6PD deficiency on risk of Plasmodium vivax infection: a case-control study amongst Afghan refugees in Pakistan. PLoS Med 7: e1000283.[Crossref]
  107. Louicharoen C, Patin E, Paul R, Nuchprayoon I, Witoonpanich B, Peerapittayamongkol C, Casademont I, Sura T, Laird NM, Singhasivanon P, Quintana-Murci L, Sakuntabhai A, , 2009. Positively selected G6PD-Mahidol mutation reduces Plasmodium vivax density in southeast Asians. Science 326: 15461549.[Crossref]
  108. O'Donnell A, Premawardhena A, Arambepola M, Samaranayake R, Allen SJ, Peto TE, Fisher CA, Cook J, Corran PH, Olivieri NF, Weatherall DJ, , 2009. Interaction of malaria with a common form of severe thalassemia in an Asian population. Proc Natl Acad Sci USA 106: 1871618721.[Crossref]
  109. Williams TN, Maitland K, Bennett S, Ganczakowski M, Peto TE, Newbold CI, Bowden DK, Weatherall DJ, Clegg JB, , 1996. High incidence of malaria in alpha-thalassaemic children. Nature 383: 522525.[Crossref]
  110. Douglas NM, John GK, von Seidlein L, Anstey NM, Price RN, , 2012. Chemotherapeutic strategies for reducing transmission of Plasmodium vivax malaria. Adv Parasitol 80: 271300.[Crossref]
  111. Zimmerman PA, Howes RE, , 2015. Malaria diagnosis for malaria elimination. Curr Opin Infect Dis 28: 446454.[Crossref]
  112. Alves FP, Durlacher RR, Menezes MJ, Krieger H, Silva LH, Camargo EP, , 2002. High prevalence of asymptomatic Plasmodium vivax and Plasmodium falciparum infections in native Amazonian populations. Am J Trop Med Hyg 66: 641648.
  113. Alves FP, Gil LH, Marrelli MT, Ribolla PE, Camargo EP, Da Silva LH, , 2005. Asymptomatic carriers of Plasmodium spp. as infection source for malaria vector mosquitoes in the Brazilian Amazon. J Med Entomol 42: 777779.[Crossref]
  114. Atkinson JA, Johnson ML, Wijesinghe R, Bobogare A, Losi L, O'Sullivan M, Yamaguchi Y, Kenilorea G, Vallely A, Cheng Q, Ebringer A, Bain L, Gray K, Harris I, Whittaker M, Reid H, Clements A, Shanks D, , 2012. Operational research to inform a sub-national surveillance intervention for malaria elimination in Solomon Islands. Malar J 11: 101.[Crossref]
  115. Coleman RE, Maneechai N, Rachaphaew N, Kumpitak C, Miller RS, Soyseng V, Thimasarn K, Sattabongkot J, , 2002. Comparison of field and expert laboratory microscopy for active surveillance for asymptomatic Plasmodium falciparum and Plasmodium vivax in western Thailand. Am J Trop Med Hyg 67: 141144.
  116. Coleman RE, Sattabongkot J, Promstaporm S, Maneechai N, Tippayachai B, Kengluecha A, Rachapaew N, Zollner G, Miller RS, Vaughan JA, Thimasarn K, Khuntirat B, , 2006. Comparison of PCR and microscopy for the detection of asymptomatic malaria in a Plasmodium falciparum/vivax endemic area in Thailand. Malar J 5: 121.[Crossref]
  117. Ganguly S, Saha P, Guha SK, Biswas A, Das S, Kundu PK, Maji AK, , 2013. High prevalence of asymptomatic malaria in a tribal population in eastern India. J Clin Microbiol 51: 14391444.[Crossref]
  118. Herdiana H, Fuad A, Asih PB, Zubaedah S, Arisanti RR, Syafruddin D, Kusnanto H, Sumiwi ME, Yuniarti T, Imran A, Rahmadyani R, Yani M, Kusriastuti R, Tarmizi SN, Laihad FJ, Hawley WA, , 2013. Progress towards malaria elimination in Sabang Municipality, Aceh, Indonesia. Malar J 12: 42.[Crossref]
  119. Kitvatanachai S, Janyapoon K, Rhongbutsri P, Thap LC, , 2003. A survey on malaria in mobile Cambodians in Aranyaprathet, Sa Kaeo Province, Thailand. Southeast Asian J Trop Med Public Health 34: 4853.
  120. Rajendran P, Rajesh PK, Thyagarajan SP, Balakrishnan P, Hari R, Joyee AG, Kurien T, Krishnmurthy P, Jacob V, , 2001. Asymptomatic malarial parasitaemia in Tamil Nadu. J Assoc Physicians India 49: 11611164.
  121. Goonewardena D, , 1998. Study of Clinical Immunity to Malaria. Colombo, Sri Lanka: University of Colombo.
  122. Doolan DL, Dobano C, Baird JK, , 2009. Acquired immunity to malaria. Clin Microbiol Rev 22: 1336.[Crossref]
  123. Barbosa S, Gozze AB, Lima NF, Batista CL, Bastos M da S, Nicolete VC, Fontoura PS, Goncalves RM, Viana SA, Menezes MJ, Scopel KK, Cavasini CE, Malafronte R dos S, da Silva-Nunes M, Vinetz JM, Castro MC, Ferreira MU, , 2014. Epidemiology of disappearing Plasmodium vivax malaria: a case study in rural Amazonia. PLoS Negl Trop Dis 8: e3109.[Crossref]
  124. Vallejo AF, Garcia J, Amado-Garavito AB, Arevalo-Herrera M, Herrera S, , 2016. Plasmodium vivax gametocyte infectivity in sub-microscopic infections. Malar J 15: 48.[Crossref]
  125. White NJ, , 2008. The role of anti-malarial drugs in eliminating malaria. Malar J 7 (Suppl 1): S8.[Crossref]
  126. McKenzie FE, Wongsrichanalai C, Magill AJ, Forney JR, Permpanich B, Lucas C, Erhart LM, O'Meara WP, Smith DL, Sirichaisinthop J, Gasser RA, Jr, 2006. Gametocytemia in Plasmodium vivax and Plasmodium falciparum infections. J Parasitol 92: 12811285.[Crossref]
  127. Moonen B, Cohen JM, Snow RW, Slutsker L, Drakeley C, Smith DL, Abeyasinghe RR, Rodriguez MH, Maharaj R, Tanner M, Targett G, , 2010. Operational strategies to achieve and maintain malaria elimination. Lancet 376: 15921603.[Crossref]
  128. White MT, Karl S, Battle KE, Hay SI, Mueller I, Ghani AC, , 2014. Modelling the contribution of the hypnozoite reservoir to Plasmodium vivax transmission. eLife 3: e04692.[Crossref]
  129. Bhatt S, Weiss DJ, Cameron E, Bisanzio D, Mappin B, Dalrymple U, Battle KE, Moyes CL, Henry A, Eckhoff PA, Wenger EA, Briet O, Penny MA, Smith TA, Bennett A, Yukich J, Eisele TP, Griffin JT, Fergus CA, Lynch M, Lindgren F, Murray CJ, Smith DL, Hay SI, Cibulskis RE, Gething PW, , 2015. The impact of malaria control on Plasmodium falciparum in Africa, 2000–2015. Nature 526: 207211.[Crossref]
  130. Hay SI, Okiro EA, Gething PW, Patil AP, Tatem AJ, Guerra CA, Snow RW, , 2010. Estimating the global clinical burden of Plasmodium falciparum malaria in 2007. PLoS Med 7: e1000290.[Crossref]
  131. Cibulskis RE, Aregawi M, Williams R, Otten M, Dye C, , 2011. Worldwide incidence of malaria in 2009: estimates, time trends, and a critique of methods. PLoS Med 8: e1001142.[Crossref]
  132. World Health Organization, 2014. World Malaria Report 2014. Geneva, Switzerland: World Health Organization, 226.
  133. Guerra CA, Hay SI, Lucioparedes LS, Gikandi PW, Tatem AJ, Noor AM, Snow RW, , 2007. Assembling a global database of malaria parasite prevalence for the Malaria Atlas Project. Malar J 6: 17.[Crossref]
  134. Patil AP, Okiro EA, Gething PW, Guerra CA, Sharma SK, Snow RW, Hay SI, , 2009. Defining the relationship between Plasmodium falciparum parasite rate and clinical disease: statistical models for disease burden estimation. Malar J 8: 186.[Crossref]
  135. Battle KE, Cameron E, Guerra CA, Golding N, Duda KA, Howes RE, Elyazar IRF, Baird JK, Reiner RC, Jr Smith DL, Gething PW, Hay SI, , 2015. Defining the relationship between Plasmodium vivax parasite rate and clinical disease. Malar J 14: 191.[Crossref]
  136. Cameron E, Battle KE, Bhatt S, Weiss DJ, Bisanzio D, Mappin B, Dalrymple U, Hay SI, Smith DL, Griffin JT, Wenger EA, Eckhoff PA, Smith TA, Penny MA, Gething PW, , 2015. Defining the relationship between infection prevalence and clinical incidence of Plasmodium falciparum malaria. Nat Commun 6: 8170.[Crossref]
  137. Battle KE, Guerra CA, Golding N, Duda KA, Cameron E, Howes RE, Elyazar IRF, Baird JK, Reiner RC, Jr Smith DL, Gething PW, Hay SI, , 2015. Global database of matched Plasmodium falciparum and P. vivax incidence and prevalence records from 1985 to 2013. Sci Data 2: 150012.[Crossref]
  138. Pampana E, , 1969. A Textbook of Malaria Eradication. London, United Kingdom: Oxford University Press.
  139. Sattabongkot J, Tsuboi T, Zollner GE, Sirichaisinthop J, Cui L, , 2004. Plasmodium vivax transmission: chances for control? Trends Parasitol 20: 192198.[Crossref]
  140. Ministry of Health Sri Lanka and World Health Organization and the University of California-San Francisco, 2012. Eliminating Malaria: Case-study 3. Progress towards Elimination in Sri Lanka. Geneva, Switzerland: World Health Organization.
  141. Coura JR, Suarez-Mutis M, Ladeia-Andrade S, , 2006. A new challenge for malaria control in Brazil: asymptomatic Plasmodium infection–a review. Mem Inst Oswaldo Cruz 101: 229237.
  142. Povoa MM, Conn JE, Schlichting CD, Amaral JC, Segura MN, Da Silva AN, Dos Santos CC, Lacerda RN, De Souza RT, Galiza D, Santa Rosa EP, Wirtz RA, , 2003. Malaria vectors, epidemiology, and the re-emergence of Anopheles darlingi in Belem, Para, Brazil. J Med Entomol 40: 379386.[Crossref]
  143. World Health Organization, 2013. World Malaria Report 2013. Geneva, Switzerland: World Health Organization, 199.
  144. Feachem RG, Phillips AA, Hwang J, Cotter C, Wielgosz B, Greenwood BM, Sabot O, Rodriguez MH, Abeyasinghe RR, Ghebreyesus TA, Snow RW, , 2010. Shrinking the malaria map: progress and prospects. Lancet 376: 15661578.[Crossref]
  145. UCSF Global Health Group and Malaria Atlas Project, 2011. Atlas of Malaria-Eliminating Countries. San Francisco, CA: University of California.
  146. World Health Organization, 2015. Confronting Plasmodium vivax Malaria. Geneva, Switzerland: World Health Organization, 12.
  147. Baird JK, , 2007. Neglect of Plasmodium vivax malaria. Trends Parasitol 23: 533539.[Crossref]
  148. Galinski MR, Barnwell JW, , 2008. Plasmodium vivax: who cares? Malar J 7 (Suppl 1): S9.[Crossref]
  149. Kochar DK, Saxena V, Singh N, Kochar SK, Kumar SV, Das A, , 2005. Plasmodium vivax malaria. Emerg Infect Dis 11: 132134.[Crossref]
  150. World Health Organization, 2012. Management of Severe Malaria: A Practical Handbook, 3rd edition. Geneva, Switzerland: World Health Organization.
  151. Kochar DK, Das A, Kochar SK, Saxena V, Sirohi P, Garg S, Kochar A, Khatri MP, Gupta V, , 2009. Severe Plasmodium vivax malaria: a report on serial cases from Bikaner in northwestern India. Am J Trop Med Hyg 80: 194198.
  152. Kochar DK, Pakalapati D, Kochar SK, Sirohi P, Khatri MP, Kochar A, Das A, , 2007. An unexpected cause of fever and seizures. Lancet 370: 908.[Crossref]
  153. Rahimi BA, Thakkinstian A, White NJ, Sirivichayakul C, Dondorp AM, Chokejindachai W, , 2014. Severe vivax malaria: a systematic review and meta-analysis of clinical studies since 1900. Malar J 13: 481.[Crossref]
  154. Douglas NM, Lampah DA, Kenangalem E, Simpson JA, Poespoprodjo JR, Sugiarto P, Anstey NM, Price RN, , 2013. Major burden of severe anemia from non-falciparum malaria species in southern Papua: a hospital-based surveillance study. PLoS Med 10: e1001575; discussion e1001575.[Crossref]
  155. Lampah DA, Yeo TW, Malloy M, Kenangalem E, Douglas NM, Ronaldo D, Sugiarto P, Simpson JA, Poespoprodjo JR, Anstey NM, Price RN, , 2014. Severe malarial thrombocytopenia: a risk factor for mortality in Papua, Indonesia. J Infect Dis 211: 623634.[Crossref]
  156. Douglas NM, Pontororing GJ, Lampah DA, Yeo TW, Kenangalem E, Poespoprodjo J, Ralph AP, Bangs MJ, Sugiarto P, Anstey NM, Price RN, , 2014. Mortality attributable to Plasmodium vivax malaria: a clinical audit from Papua, Indonesia. BMC Med 12: 217.[Crossref]
  157. Rajahram GS, Barber BE, William T, Grigg MJ, Menon J, Yeo TW, Anstey NM, , 2016. Falling Plasmodium knowlesi malaria death rate among adults despite rising incidence, Sabah, Malaysia, 2010–2014. Emerg Infect Dis 22: 4148.[Crossref]
  158. World Health Organization, 2015. Control and Elimination of Plasmodium vivax Malaria: A Technical Brief. Geneva, Switzerland: World Health Organization, 64.
  159. Scott JAG, Berkley JA, Mwangi I, Ochola L, Uyoga S, Macharia A, Ndila C, Lowe BS, Mwarumba S, Bauni E, Marsh K, Williams TN, , 2011. Relation between falciparum malaria and bacteraemia in Kenyan children: a population-based, case-control study and a longitudinal study. Lancet 378: 13161323.[Crossref]
  160. Olupot-Olupot P, Urban BC, Jemutai J, Nteziyaremye J, Fanjo HM, Karanja H, Karisa J, Ongodia P, Bwonyo P, Gitau EN, Talbert A, Akech S, Maitland K, , 2013. Endotoxaemia is common in children with Plasmodium falciparum malaria. BMC Infect Dis 13: 117.[Crossref]
  161. Hochman S, Kim K, , 2012. The impact of HIV coinfection on cerebral malaria pathogenesis. J Neuroparasitology 3: 235547.[Crossref]
  162. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, Drake JM, Brownstein JS, Hoen AG, Sankoh O, Myers MF, George DB, Jaenisch T, Wint GR, Simmons CP, Scott TW, Farrar JJ, Hay SI, , 2013. The global distribution and burden of dengue. Nature 496: 504507.[Crossref]
  163. Golding N, Wilson AL, Moyes CL, Cano J, Pigott DM, Velayudhan R, Brooker SJ, Smith DL, Hay SI, Lindsay SW, , 2015. Integrating vector control across diseases. BMC Med 13: 249.[Crossref]
  164. Mushtaq MB, Qadri MI, Rashid A, , 2013. Concurrent infection with dengue and malaria: an unusual presentation. Case Rep Med 2013: 520181.
  165. Magalhaes BM, Alexandre MA, Siqueira AM, Melo GC, Gimaque JB, Bastos MS, Figueiredo RM, Carvalho RC, Tavares MA, Naveca FG, Alonso P, Bassat Q, Lacerda MV, Mourao MP, , 2012. Clinical profile of concurrent dengue fever and Plasmodium vivax malaria in the Brazilian Amazon: case series of 11 hospitalized patients. Am J Trop Med Hyg 87: 11191124.[Crossref]
  166. Deresinski S, , 2006. Concurrent Plasmodium vivax malaria and dengue. Emerg Infect Dis 12: 1802.[Crossref]
  167. Carme B, Matheus S, Donutil G, Raulin O, Nacher M, Morvan J, , 2009. Concurrent dengue and malaria in Cayenne Hospital, French Guiana. Emerg Infect Dis 15: 668671.[Crossref]
  168. Thangaratham PS, Jeevan MK, Rajendran R, Samuel PP, Tyagi BK, , 2006. Dual infection by dengue virus and Plasmodium vivax in Alappuzha District, Kerala, India. Jpn J Infect Dis 59: 211212.
  169. GAHI, 2014. Global Atlas of Helminth Infections. Available at: www.thiswormyworld.org. Accessed December 28, 2014.
  170. Melo GC, Reyes-Lecca RC, Vitor-Silva S, Monteiro WM, Martins M, Benzecry SG, Alecrim M, Lacerda MV, , 2010. Concurrent helminthic infection protects schoolchildren with Plasmodium vivax from anemia. PLoS One 5: e11206.[Crossref]
  171. Boel M, Carrara VI, Rijken M, Proux S, Nacher M, Pimanpanarak M, Paw MK, Moo O, Gay H, Bailey W, Singhasivanon P, White NJ, Nosten F, McGready R, , 2010. Complex interactions between soil-transmitted helminths and malaria in pregnant women on the Thai-Burmese border. PLoS Negl Trop Dis 4: e887.[Crossref]
  172. Williams TN, Maitland K, Phelps L, Bennett S, Peto TE, Viji J, Timothy R, Clegg JB, Weatherall DJ, Bowden DK, , 1997. Plasmodium vivax: a cause of malnutrition in young children. QJM 90: 751757.[Crossref]
  173. Baird JK, Valecha N, Duparc S, White NJ, Price RN, , 2016. Diagnosis and treatment of Plasmodium vivax malaria. Am J Trop Med Hyg 95 (Suppl 6): 3551.[Crossref]
  174. Sumawinata IW, Bernadeta Leksana B, Sutamihardja A, Purnomo Subianto B, Sekartuti Fryauff DJ, Baird JK, , 2003. Very high risk of therapeutic failure with chloroquine for uncomplicated Plasmodium falciparum and P. vivax malaria in Indonesian Papua. Am J Trop Med Hyg 68: 416420.
  175. Baird JK, Leksana B, Masbar S, Fryauff DJ, Sutanihardja MA, Suradi Wignall FS, Hoffman SL, , 1997. Diagnosis of resistance to chloroquine by Plasmodium vivax: timing of recurrence and whole blood chloroquine levels. Am J Trop Med Hyg 56: 621626.
  176. Asih PB, Syafruddin D, Leake J, Sorontou Y, Sadikin M, Sauerwein RW, Vinetz J, Baird JK, , 2011. Phenotyping clinical resistance to chloroquine in Plasmodium vivax in northeastern Papua, Indonesia. Int J Parasitol Drugs Drug Resist 1: 2832.[Crossref]
  177. World Health Organization, 2009. Methods for Surveillance of Antimalarial Drug Efficacy. Geneva, Switzerland: World Health Organization.
  178. Rieckmann KH, Davis DR, Hutton DC, , 1989. Plasmodium vivax resistance to chloroquine? Lancet 2: 11831184.[Crossref]
  179. Karunajeewa HA, Mueller I, Senn M, Lin E, Law I, Gomorrai PS, Oa O, Griffin S, Kotab K, Suano P, Tarongka N, Ura A, Lautu D, Page-Sharp M, Wong R, Salman S, Siba P, Ilett KF, Davis TM, , 2008. A trial of combination antimalarial therapies in children from Papua New Guinea. N Engl J Med 359: 25452557.[Crossref]
  180. Ratcliff A, Siswantoro H, Kenangalem E, Wuwung M, Brockman A, Edstein MD, Laihad F, Ebsworth EP, Anstey NM, Tjitra E, Price RN, , 2007. Therapeutic response of multidrug-resistant Plasmodium falciparum and P. vivax to chloroquine and sulfadoxine-pyrimethamine in southern Papua, Indonesia. Trans R Soc Trop Med Hyg 101: 351359.[Crossref]
  181. Sutanto I, Suprijanto S, Nurhayati Manoempil P, Baird JK, , 2009. Resistance to chloroquine by Plasmodium vivax at Alor in the Lesser Sundas Archipelago in eastern Indonesia. Am J Trop Med Hyg 81: 338342.
  182. Price RN, von Seidlein L, Valecha N, Nosten F, Baird JK, White NJ, , 2014. Global extent of chloroquine-resistant Plasmodium vivax: a systematic review and meta-analysis. Lancet Infect Dis 14: 982991.[Crossref]
  183. de Santana Filho FS, Arcanjo AR, Chehuan YM, Costa MR, Martinez-Espinosa FE, Vieira JL, Barbosa MG, Alecrim WD, Alecrim MG, , 2007. Chloroquine-resistant Plasmodium vivax, Brazilian Amazon. Emerg Infect Dis 13: 11251126.[Crossref]
  184. Tabernero P, Fernandez FM, Green M, Guerin PJ, Newton PN, , 2014. Mind the gaps–the epidemiology of poor-quality anti-malarials in the malarious world–analysis of the WorldWide Antimalarial Resistance Network database. Malar J 13: 139.[Crossref]
  185. Baird JK, , 2011. Resistance to chloroquine unhinges vivax malaria therapeutics. Antimicrob Agents Chemother 55: 18271830.[Crossref]
  186. Harijanto PN, , 2010. Malaria treatment by using artemisinin in Indonesia. Acta Med Indones 42: 5156.
  187. Douglas NM, Anstey NM, Angus BJ, Nosten F, Price RN, , 2010. Artemisinin combination therapy for vivax malaria. Lancet Infect Dis 10: 405416.[Crossref]
  188. Ingram RJ, Crenna-Darusallam C, Soebianto S, Noviyanti R, Baird JK, , 2014. The clinical and public health problem of relapse despite primaquine therapy: case review of repeated relapses of Plasmodium vivax acquired in Papua New Guinea. Malar J 13: 488.[Crossref]
  189. Bennett JW, Pybus BS, Yadava A, Tosh D, Sousa JC, McCarthy WF, Deye G, Melendez V, Ockenhouse CF, , 2013. Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria. N Engl J Med 369: 13811382.[Crossref]
  190. Bassat Q, Velarde M, Mueller I, Lin J, Leslie T, Wongsrichanalai C, Baird JK, , 2016. Key knowledge gaps for Plasmodium vivax control and elimination. Am J Trop Med Hyg 95 (Suppl 6): 6271.[Crossref]
  191. Golding N, , 2014. ageStand R Package. Available at: https://github.com/SEEG-Oxford: GitHub. Accessed May 20, 2015.
  192. Okell LC, Bousema T, Griffin JT, Ouedraogo AL, Ghani AC, Drakeley CJ, , 2012. Factors determining the occurrence of submicroscopic malaria infections and their relevance for control. Nat Commun 3: 1237.[Crossref]
  193. White NJ, Pukrittayakamee S, Hien TT, Faiz MA, Mokuolu OA, Dondorp AM, , 2013. Malaria. Lancet 383: 723735.[Crossref]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.16-0141
Loading
/content/journals/10.4269/ajtmh.16-0141
Loading

Data & Media loading...

  • Received : 24 Feb 2016
  • Accepted : 19 Apr 2016

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error